Study on Cost-Effectiveness of Personality disorder TREatment

ISRCTN ISRCTN73817429
DOI https://doi.org/10.1186/ISRCTN73817429
Secondary identifying numbers N/A
Submission date
28/12/2006
Registration date
28/12/2006
Last edited
16/01/2007
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr Helene Andrea
Scientific

Viersprong Institute for Studies on Personality Disorders (VISPD)
P.O. Box 7
Halsteren
4660 AA
Netherlands

+31 (0)16 463 2200
helene.andrea@deviersprong.nl

Study information

Study designNon-randomised clinical trial
Primary study designInterventional
Secondary study designMulti-centre
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymSCEPTRE
Study objectives1. Effect sizes of the psychotherapeutic treatments vary between 0.5 and 2.0.
2. A lower dosage of psychotherapeutic treatment is mainly related to symptomatic improvement, while a higher dosage is also related to structural and functional improvement.
3. The dosage for an optimal cost-effectiveness is lower than the maximum dosage.
4. When compared to cluster B personality disorders, for cluster C personality disorders a lower dosage is required to reach optimal cost-effectiveness.
5. A lower level of psychological mindedness and/or ability for a positive working alliance with the therapist is related to a lower level of (cost)-effectiveness.
Ethics approval(s)Approval received from the Research Ethics Committee (REC) of Erasmus Medical Centre, Rotterdam, on the 7th January 2004 (ref: MEC 229.834/2003/122).
Health condition(s) or problem(s) studiedPersonality Disorder
InterventionPsychotherapeutic treatment programs for patients with personality pathology that will be distinguished from one another according to the following dosages:
1. Short (maximum of six months) outpatient
2. Short day hospital
3. Short inpatient
4. Long (at least six months) outpatient
5. Long day hospital
6. Long inpatient
Intervention typeOther
Primary outcome measure1. Structural improvement of personality pathology (assessed with the Outcome Questionnaire [OQ45], and the Severity Indices of Personality Problems [SIPP])
2. Quality Adjusted Life Years (QALYs)
Secondary outcome measures1. Symptomatic improvement (assessed with the Symptoms CheckList [SCL-90])
2. Functional improvement (assessed with, amongst others, questions regarding work situation and care consumption)
3. Quality of life
Overall study start date01/09/2003
Completion date31/12/2008

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants821
Key inclusion criteria1. At least one Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) axis-II diagnosis
2. An indication for psychotherapeutic treatment aiming at structural improvement of the personality pathology (besides symptomatic and/or functional improvement)
Key exclusion criteria1. Insufficient command of Dutch language
2. Severe cognitive impairments
3. Mental retardation
4. Axis-I schizophrenia
Date of first enrolment01/09/2003
Date of final enrolment31/12/2008

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Viersprong Institute for Studies on Personality Disorders (VISPD)
Halsteren
4660 AA
Netherlands

Sponsor information

Funders

Funder type

Hospital/treatment centre

Psychotherapeutic Center De Viersprong (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan
BMC - Part of Springer Nature Springer Nature